Latest Dermatology research

Top 10 this week

Week of 20 September 2026

1. 1

   Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era

   European journal of cancer (Oxford, England : 1990) · Q1 journal · RCT · Evidence level 1 (High) · 10 September 2026

   A decision-analysis using trial data showed that patients who forgo sentinel lymph node biopsy and receive neoadjuvant anti-PD-1 plus anti-CTLA-4 therapy at nodal recurrence achieve an 8 to 19 percentage-point gain in distant metastasis-free survival compared with the traditional biopsy-then-adjuvant-immunotherapy pathway. The benefit varies with tumor thickness, prompting calls for a randomized trial to confirm whether SLNB can be safely omitted in modern melanoma care.

2. 2

   Comparative Efficacy of Topical Trichloroacetic Acid and Superficial Cryotherapy in Resistant Alopecia Areata: A Randomized Clinical Trial

   The Journal of clinical and aesthetic dermatology · Q2 journal · RCT · Evidence level 1 (High) · 1 July 2026

   RCT comparing TCA vs cryotherapy for alopecia areata

3. 3

   Efficacy of Histaglobulin in Allergic Diseases: A Systematic Review and Meta-Analysis with Implications for Allergic Rhinitis

   International journal of molecular sciences · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 29 August 2026

   Systematic review/meta‑analysis of histaglobulin in allergic disease

4. 4

   The Evolving Role of Artificial Intelligence in Dermatology: A Meta-Analysis of Diagnostic Performance, Clinical Applications, and Implementation Challenges (2003-2025)

   Diagnostics (Basel, Switzerland) · Q2 journal · SR/MA of RCTs · Evidence level 1 (High) · 31 August 2026

   Meta‑analysis of AI diagnostic performance in dermatology

5. 5

   Gamification of dermatology diagnostics training: a nationwide, randomized, controlled trial of 34,556 cases

   Clinical and experimental dermatology · Q2 journal · RCT · Evidence level 1 (High) · 17 September 2026

   In a nationwide trial of 71 medical students, daily leaderboards caused participants to complete about three times more dermatology cases than controls (785 vs 240). However, post-test scores rose only marginally and did not differ between groups, suggesting that competition boosted activity but not learning. Further research is needed to find training methods that translate effort into skill.

6. 6

   Corticosteroids as adjunctive therapy to standard treatment in Kawasaki disease: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

   European journal of pediatrics · Q1 journal · SR/MA of RCTs · Evidence level 1 (High) · 14 September 2026

   Corticosteroids adjunctive therapy in Kawasaki disease systematic review

7. 7

   Excimer laser angioplasty for acute coronary occlusion: a stratified meta-analysis of efficacy against aspiration thrombectomy and conventional PCI

   Lasers in medical science · Q2 journal · SR/MA of RCTs · Evidence level 1 (High) · 15 September 2026

   High-quality evidence in a top journal

8. 8

   Single-session extraoral photobiomodulation reduces early postoperative pain but not edema or trismus after impacted mandibular third molar extraction: a randomized controlled trial

   Lasers in medical science · Q2 journal · RCT · Evidence level 1 (High) · 16 September 2026

   Dental photobiomodulation trial, no skin relevance

9. 9

   Efficacy of an Adhesive Hydrocolloid Bandage on Wound Healing: Findings of a 28-Day, Single-Centre, Randomised, Controlled Study

   International wound journal · Q1 journal · RCT · Evidence level 1 (High) · 1 September 2026

   High-quality evidence in a top journal

10. 10

    Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · Q1 journal · RCT · Evidence level 1 (High) · 17 September 2026

    In a phase III trial of 93 survivors, a 7-week self-acupressure program reduced the combined fatigue-sleep-depression score and each individual symptom more than sham or usual care, with benefits persisting to week 19 and no adverse events. Quality of life also rose, though the modest cost advantage remains unclear.

Paper of the day, last two weeks

• Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry

  Journal of the American Academy of Dermatology · Q1 journal · Unclassified · Evidence level 5 (Expert Opinion) · 21 September 2026

  Atopic dermatitis outcomes by skin colour

• Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3-6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use

  Journal of clinical medicine · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 26 August 2026

  36‑month real‑world upadacitinib data in atopic dermatitis

• Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3-6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use

  Journal of clinical medicine · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 26 August 2026

  36‑month real‑world upadacitinib data in atopic dermatitis

• Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3-6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use

  Journal of clinical medicine · Q1 journal · Retrospective cohort · Evidence level 3 (Low) · 26 August 2026

  36‑month real‑world upadacitinib data in atopic dermatitis

• Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis

  JAMA dermatology · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 16 September 2026

  Long‑term dupilumab effectiveness and safety in pediatric AD

• Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases

  European journal of cancer (Oxford, England : 1990) · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 10 September 2026

  In a retrospective Swedish cohort of 189 melanoma patients with brain mets, the flipped schedule (nivolumab 3 mg/kg + ipilimumab 1 mg/kg) was linked to a 46% lower risk of death and a 44% lower risk of progression compared with the traditional schedule, while more patients completed all four induction doses and severe immune-related toxicity was modestly lower.

• Site-Specific Response and Psychosocial Outcomes in Head and Neck Atopic Dermatitis Treated with Tralokinumab: A Prospective Real-World Study

  Dermatitis : contact, atopic, occupational, drug · Q1 journal · Unclassified · Evidence level 5 (Expert Opinion) · 11 September 2026

  Head & neck AD outcomes with tralokinumab

• Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma

  International journal of cancer · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 9 September 2026

  Early cessation of adjuvant anti‑PD‑1 worsens melanoma outcomes

• Incident psoriasis in atopic dermatitis: a large-scale cohort study of disease- and treatment-associated risks

  Frontiers in immunology · Q1 journal · Cohort · Evidence level 3 (Low) · 28 August 2026

  AD associated with incident psoriasis; biologic risk

• Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma

  International journal of cancer · Q1 journal · Prospective cohort · Evidence level 2 (Moderate) · 9 September 2026

  Early cessation of adjuvant anti‑PD‑1 worsens melanoma outcomes

• IMPACT study: large real-world evaluation of guselkumab in psoriatic arthritis integrating clinical response and treatment persistence

  Therapeutic advances in musculoskeletal disease · Q1 journal · RCT · Evidence level 1 (High) · 8 September 2026

  In a multicentre real-world cohort of 389 psoriatic arthritis patients, median DAPSA fell from 24.2 to 10.5, with 58.6% reaching low disease activity and 14.1% in remission at one year. Skin clearance was complete in 68% and enthesitis/dactylitis resolved in 63% and 95% respectively, while 79% remained on therapy with no new safety signals.

• Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study

  The British journal of dermatology · Q1 journal · RCT · Evidence level 1 (High) · 10 September 2026

  In a prospective cohort of 903 primary cutaneous squamous cell carcinomas, five-year recurrence was 1.7% after standard excision and 3.3% after Mohs micrographic surgery, a difference that was not statistically significant after adjusting for tumor stage. Mohs produced much smaller surgical defects, supporting its role when tissue preservation matters, but larger trials are needed to confirm any efficacy advantage.

• Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States

  The Journal of dermatological treatment · Q1 journal · Unclassified · Evidence level 5 (Expert Opinion) · 7 September 2026

  Ruxolitinib cream reduces BSA and severity in moderate AD

• Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update

  The Journal of dermatological treatment · Q1 journal · Guideline · Evidence level 1 (High) · 7 September 2026

  Saudi guidelines for moderate‑to‑severe psoriasis 2026

Evidence summaries in Dermatology

• Atopic Dermatitis
• Psoriasis
• Acne
• Hidradenitis Suppurativa
• Pyoderma Gangrenosum